MHC Multimer Proficiency Panel
In collaboration with CIC (the US Cancer Immuno-therapy Consortium of the CRI) and CIMT (the European Association for Cancer Immunotherapy), Immudex offers Proficiency Panels as a non-profit service to help researchers and clinicians worldwide evaluate and compare their immune monitoring performance with MHC Multimers.
Using laboratory-specific protocols, antibodies, and flow cytometry, participants determine the number of antigen-specific T cells in provided PBMC samples using MHC multimers and receive a report comparing the results from all participating laboratories.
What You Receive
PBMC samples: identical for all participants*
If requested, MHC Dextramer® reagents free of charge (only pay shipping fees)
What You Measure
Total number of CD8+ T cells in samples
Number of MHC multimer+ CD8+ T cells in samples
Percent of total CD8+ T cells that are MHC multimer+
MHC Multimer Proficiency Panel – Step-by-Step
Proficiency Performance 2021
In the MHC Multimer Proficiency Panel 2021, all laboratories received identical PBMC samples for identification of antigen-specific T-cells using MHC multimers, and results were collated to assess the relative accuracy of results across the different laboratories. 13 out of 19 participants (68,4%) had a relative accuracy between 0.66 – 1.5 and were considered to be in “the average range” (dark blue columns).
Learn more in the MHC Multimer Proficiency Panel Report 2021
*Immudex conducts quality control of the PBMC samples before these are shipped to participants.
|Academia and Non-profit Organizations||1400 EUR / 1600 USD|
|Zero-revenue biotech companies||1850 EUR / 2100 USD|
|Positive-revenue biotech companies||2450 EUR / 2800 USD|
|Pharmaceutical companies and CROs||2750 EUR / 3150 USD|